Literature DB >> 14712311

Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis.

D L Mattey1, N B Nixon, P T Dawes, W E R Ollier, A H Hajeer.   

Abstract

Matrix metalloproteinases (MMPs) are implicated in joint destruction in rheumatoid arthritis (RA). We investigated whether the 5A/6A polymorphism within the MMP-3 (stromelysin-1) gene promoter region is associated with disease outcome in 254 patients with established RA. Patients homozygous for the MMP-3 6A allele had more radiographic damage (measured by Larsen score) than those with other genotypes (109.8 vs 91.1, P=0.04). Patients with the 6A/6A genotype also had more functional impairment and higher serum proMMP-3 levels, although only the latter was significant (P=0.002). A possible association was found between homozygosity for the 6A allele and carriage of the RA-associated HLA-DRB1 shared epitope (SE). Combination of these factors was associated with more severe disease than the SE alone. The data suggest that the MMP-3 6A/6A genotype is associated with worse RA outcome, and that this genotype may have an additive effect with the SE on disease severity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712311     DOI: 10.1038/sj.gene.6364050

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  13 in total

Review 1.  MMPs as therapeutic targets--still a viable option?

Authors:  Barbara Fingleton
Journal:  Semin Cell Dev Biol       Date:  2007-07-06       Impact factor: 7.727

2.  Association of MMP-3 (-1612 5A/6A) polymorphism with knee osteoarthritis in Thai population.

Authors:  Sittisak Honsawek; Somkiat Malila; Pongsak Yuktanandana; Aree Tanavalee; Benjamad Deepaisarnsakul; Javad Parvizi
Journal:  Rheumatol Int       Date:  2012-03-29       Impact factor: 2.631

3.  NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter.

Authors:  Ruth C Borghaei; Grzegorz Gorski; Masoud Javadi
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

4.  Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis.

Authors:  Sabrina Scherer; Thais Barboza de Souza; Juliana de Paoli; Claiton Viegas Brenol; Ricardo Machado Xavier; João Carlos Tavares Brenol; José Artur Chies; Daniel Simon
Journal:  Rheumatol Int       Date:  2009-06-06       Impact factor: 2.631

5.  Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population.

Authors:  H J Lee; G H Lee; S Nah; K H Lee; H Yang; Y M Kim; W Chun; S Hong; S Kim
Journal:  Rheumatol Int       Date:  2008-02-27       Impact factor: 2.631

6.  Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study.

Authors:  Julio Rodriguez-Lopez; Eva Perez-Pampin; Juan J Gomez-Reino; Antonio Gonzalez
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

Review 8.  Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.

Authors:  Björn Pasternak; Per Aspenberg
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

9.  Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.

Authors:  Mahmood M T M Ally; Bridget Hodkinson; Pieter W A Meyer; Eustasius Musenge; Mohammed Tikly; Ronald Anderson
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

Review 10.  Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets.

Authors:  Annette H M van der Helm-van Mil; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2008-03-31       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.